Ramucirumab is a fully human IgG1 monoclonal antibody that binds to the vascular endothelial growth factor receptor 2 (VEGFR2) and inhibits association with its ligands (VEGF A, C, and D). This prevents VEGF-mediated proliferation, migration of endothelial cells, and angiogenesis. Ramucirumab was developed by ImClone Systems and received FDA approval in 2014 for the treatment of advanced gastric cancer/gastro-esophageal junction (GEJ) adenocarcinoma. Recently, Ramucirumab has also been approved for use in combination treatment of metastatic non-small lung carcinoma (NSLC), metastatic colorectal cancer (mCRC), and hepatocellular carcinoma (HCC). Ramucirumab is currently marketed under the trade name CYRAMZA®.
In PBS, pH 7.5